Clinical researchers have investigated these effects through several clinical trial programs, particularly SURPASS and SURMOUNT. The SURPASS studies primarily examined adults with type 2 diabetes, while the SURMOUNT studies focused on people with obesity or overweight.
The major areas examined in clinical research include:
Blood glucose regulation: Researchers measured changes in glycated hemoglobin (HbA1c), which indicates average blood glucose levels over approximately three months.
Body weight changes: Trials evaluated average weight reduction across different tirzepatide dosage groups.
Insulin response: Studies examined how the medication influences insulin secretion and glucose regulation.
Appetite and digestion: Researchers investigated changes in appetite, food intake, and gastric emptying.
Metabolic health: Clinical assessments included changes in waist circumference, blood pressure, and other metabolic indicators.
The SURPASS clinical trial program demonstrated improvements in blood glucose control and reductions in body weight among participants with type 2 diabetes. The SURMOUNT-1 research also reported substantial weight reduction compared with placebo in adults with obesity or overweight without diabetes.
Clinical research has expanded beyond blood glucose and weight management to examine cardiovascular outcomes, long-term treatment responses, and potential adverse effects.
The SURPASS-CVOT trial investigated cardiovascular outcomes in people with type 2 diabetes and established cardiovascular disease. It compared tirzepatide with dulaglutide, another medication used to manage type 2 diabetes.
The study included more than 13,000 participants. Results showed that tirzepatide was noninferior to dulaglutide for the combined outcome of cardiovascular death, nonfatal heart attack, or nonfatal stroke. However, the study did not establish cardiovascular superiority over dulaglutide.
Other important research findings include:
Weight management outcomes: Long-term SURMOUNT-1 findings demonstrated sustained weight reduction during treatment among participants with obesity and prediabetes.
Diabetes prevention: In the three-year study, fewer participants receiving tirzepatide developed type 2 diabetes compared with those receiving placebo.
Heart failure research: The SUMMIT trial examined participants with obesity and heart failure with preserved ejection fraction. Researchers observed fewer cardiovascular death or worsening heart failure events in the tirzepatide group than in the placebo group.
Gastrointestinal effects: Nausea, diarrhea, vomiting, constipation, and reduced appetite were among the commonly reported adverse effects.
Treatment tolerability: Gastrointestinal symptoms were generally more noticeable during dosage increases and could influence treatment continuation.
Long-term safety: Researchers continue to evaluate treatment responses, adverse events, and outcomes across different patient populations.
Clinical findings also highlight the importance of understanding treatment limitations. Tirzepatide may not be appropriate for everyone, and its prescribing information includes warnings concerning serious adverse reactions, including pancreatitis, gallbladder problems, and severe gastrointestinal reactions. It also carries a boxed warning regarding thyroid C-cell tumors observed in rodents and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Clinical research provides evidence about tirzepatide's effects on glucose regulation, weight reduction, and selected cardiovascular outcomes. The results vary according to participants' health conditions, treatment duration, dosage, and individual responses. Medical supervision remains important when evaluating its potential benefits and risks.